metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)
versus everolimus
	nivolumab alone vs. everolimus	1	-768 [-1449; -86] /10000 183/410 vs. 215/411	-78 [-646; 489] /10000 318/410 vs. 322/411	-